- ADU-S100 (MIW815) + spartalizumab combination data demonstrated antitumor activity in anti-PD-1-naïve triple-negative breast cancer (TNBC) and previously immunotherapy-treated melanoma
- As of the
April 5, 2019data cut-off, five patients treated in the weekly dosing schedule group achieved confirmed responses, one of which was a complete response (CR)
- Of the eight TNBC patients evaluable for efficacy, one anti-PD-1 naïve TNBC patient achieved a CR and two anti-PD-1 naïve TNBC patients achieved partial responses (PRs)
- Of the 25 melanoma patients radiologically evaluable for efficacy, two previously immunotherapy-treated melanoma patients achieved PRs
“We are pleased with the clinical progress to date of ADU-S100 in combination with spartalizumab,” said
Isaacs continued, “Our goal remains for ADU-S100 to be broadly explored as a combination agent, given our belief in the synergistic effects of STING agonism with checkpoint inhibitor therapy. Enrollment in our study of ADU-S100 and ipilimumab in relapsed/refractory melanoma is ongoing and we anticipate initiation of our study of ADU-S100 and pembrolizumab in first line head and neck cancer in the second half of 2019.”
Study Design and Findings from Ongoing Phase 1b Trial of ADU-S100 (MIW815) + Spartalizumab (Data cut-off:
The Phase 1b multi-center, open-label, dose-escalation clinical trial (see www.clinicaltrials.gov, identifier NCT03172936) enrolled patients with advanced, metastatic treatment-relapsed/refractory solid tumors or lymphomas and evaluated two treatment schedules. All patients received a fixed dose of 400 mg of intravenous (IV) spartalizumab on day 1 and either an intratumoral (IT) injection of ADU-S100 (MIW815) on days 1, 8 and 15 in a 28-day cycle or an IT injection of ADU-S100 (MIW815) on day 1 of every 28-day cycle. Data presented were based on findings from 83 enrolled patients, with 53 patients in the weekly group and 30 patients in the monthly group.
No dose-limiting toxicities were reported during the first cycle in any of the 50 – 1,600 µg dose cohorts. The adverse events of the combination of ADU-S100 (MIW815) and spartalizumab reported were no more frequent or severe than those reported in either single agent trial. The most common (≥5 percent of patients) treatment-related adverse events (TRAEs) of any grade were injection site pain (13.3 percent), pyrexia (12.0 percent), diarrhea (9.6 percent) and rash (6.0 percent). Grade 3/4 TRAEs (in ≥2 pts) were increased lipase (3.6 percent), diarrhea, increased ALT and increased AST (all 2.4 percent). Treatment was discontinued in two patients due to adverse events (2.4 percent).
- Five patients enrolled in the weekly group achieved confirmed responses – one CR and two PRs in anti-PD-1-naïve TNBC, as well as two PRs in previously immunotherapy-treated melanoma.
- Eight of the 11 enrolled TNBC patients were evaluable for efficacy. Of the eight evaluable TNBC patients, the three patients with a CR/PR are continuing to receive treatment. Of the three unevaluable TNBC patients, one patient discontinued the study early due to toxicity (pneumonitis) and the two remaining patients are too early for assessment.
- Twenty-five of the 35 melanoma patients were radiologically evaluable for efficacy. Of the 25 evaluable melanoma patients, the two patients with a PR stayed on treatment for over five months and eight months, respectively. Nine melanoma patients achieved stable disease (SD). Of the 10 unevaluable melanoma patients, seven patients were ongoing as of the data cut-off and were too early for assessments, two patients discontinued due to clinical progression and one patient chose to start another treatment.
- In the weekly group, 12 patients achieved SD, including five patients who maintained SD for five months or more. The SD patients had the following tumor types: sarcoma, melanoma (7), squamous cell carcinoma of the skin, breast, lymphoma and head and neck. Eight patients with SD received prior immunotherapy.
- In the monthly group, six patients achieved SD, including five patients who maintained SD for five months or more. The SD patients had the following tumor types: cutaneous melanoma, head and neck, ovarian (2), uveal melanoma and breast. Five patients with SD received prior immunotherapy.
- Among the five confirmed responders in the weekly group, the median was a 73 percent maximum reduction in the sum of the target lesion diameters.
About STING Pathway Activator Technology
The Aduro-proprietary STING pathway activator product candidates, including ADU-S100 (MIW815), are synthetic small molecule immune modulators that are designed to target and activate human STING. STING is generally expressed at high levels in immune cells, including dendritic cells. Natural activation of STING is not always sufficient to prevent the growth and spread of cancer cells. In preclinical models, ADU-S100 (MIW815) directly activates STING to further amplify the natural anti-tumor response. Once activated, the STING receptor initiates a profound innate immune response through multiple pathways, inducing the expression of a broad profile of cytokines, including interferons and chemokines. This subsequently leads to the development of a systemic tumor antigen-specific T cell adaptive immune response.
Aduro’s lead molecule, ADU-S100 (MIW815), is the first therapeutic in development specifically targeting STING. In collaboration with
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential for ADU-S100 (MIW815) alone or in combination, the completion of dose escalation, the continued evaluation of pharmacodynamic biomarker activity alone or together with
|Investor Relations Contact:||Media Contact:|
|Noopur Liffick||Aljanae Reynolds|
Source: Aduro Biotech, Inc.